magrolimab: Clinical Trials

17 trials of magrolimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 terminated, 3 withdrawn, 1 completed. 17 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 217Terminated 13, Withdrawn 3, Completed 1
Phase 16Terminated 4, Completed 1, Withdrawn 1

Follow magrolimab: new trials by email Literature Review of magrolimab trials Research Report on magrolimab

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Sabatolimab, Magrolimab, Azacitidine - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnNovartis Pharmaceuticals2024-12-202024-04-11
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
Magrolimab, 7+3, CPX-351 - Acute Myeloid Leukemia, Myelodysplastic Neoplasm
Phase 2WithdrawnUwe Platzbecker2024-03-312024-02-12
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Pembrolizumab, Magrolimab, cetuximab - Head Neck, Squamous Cell Carcinoma of Head and Neck
Phase 2TerminatedM.D. Anderson Cancer Center42023-11-282025-10-22
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
Magrolimab, Rituximab, CAR T leukapheresis - Large B-cell Lymphoma, B-cell Lymphoma
Phase 2WithdrawnM.D. Anderson Cancer Center2023-09-302023-11-13
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
Decitabine/Cedazuridine, Magrolimab - Myelodysplastic Syndromes
Phase 2TerminatedAstex Pharmaceuticals, Inc.22023-06-272024-10-02
Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Magrolimab, Bevacizumab, Irinotecan - Metastatic Colorectal Cancer
Phase 2TerminatedGilead Sciences772022-07-082025-07-01
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Magrolimab, Pembrolizumab, PET/CT - Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Phase 2TerminatedRanjana Advani82022-06-212026-06-30
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Magrolimab, Nab-Paclitaxel, Paclitaxel - Triple-Negative Breast Cancer
Phase 2TerminatedGilead Sciences922021-12-142025-11-04
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Magrolimab, Daratumumab, Pomalidomide - Multiple Myeloma
Phase 2TerminatedGilead Sciences362021-11-092025-05-02
Study of Magrolimab in Patients With Solid Tumors
Magrolimab, Docetaxel - Solid Tumor
Phase 2TerminatedGilead Sciences1062021-10-012025-05-08
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Magrolimab, Pembrolizumab, Docetaxel - Head and Neck Squamous Cell Carcinoma
Phase 2TerminatedGilead Sciences1932021-09-072025-11-19
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Magrolimab, Azacitidine, Venetoclax - Myeloid Malignancies
Phase 2TerminatedGilead Sciences542021-06-282025-03-20
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)82021-04-062025-10-16
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Azacitidine, Magrolimab, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center1102020-07-282026-04-23
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Atezolizumab, Enfortumab Vedotin, Niraparib - Urothelial Carcinoma, Bladder Cancer
Phase 1 / Phase 2TerminatedHoffmann-La Roche2722019-06-012026-08-03
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Magrolimab, Rituximab, Gemcitabine - Non Hodgkin Lymphoma
Phase 1 / Phase 2TerminatedGilead Sciences1782016-11-212025-05-29
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
Magrolimab, Cetuximab - Solid Tumor, Colorectal Cancer
Phase 1 / Phase 2CompletedGilead Sciences782016-11-022021-03-01

Conditions studied

Leukemia, Myeloid, Acute (3)  ·  Colorectal Neoplasms (2)  ·  Myelodysplastic Syndromes (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Carcinoma, Transitional Cell (1)  ·  Hodgkin Disease (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)  ·  Mycosis Fungoides (1)  ·  Recurrence (1)  ·  Sezary Syndrome (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

Gilead Sciences (8)  ·  M.D. Anderson Cancer Center (3)  ·  Astex Pharmaceuticals, Inc. (1)  ·  Hoffmann-La Roche (1)  ·  National Cancer Institute (NCI) (1)  ·  Novartis Pharmaceuticals (1)  ·  Ranjana Advani (1)  ·  Uwe Platzbecker (1)

Countries

United States (14)  ·  United Kingdom (6)  ·  Australia (5)  ·  France (4)  ·  Spain (4)  ·  Hong Kong (3)  ·  Belgium (2)  ·  Canada (2)  ·  Germany (2)  ·  Italy (2)  ·  Poland (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Czechia (1)  ·  Greece (1)

Top investigators

Michael S Khodadoust (1)  ·  Naval G Daver (1)  ·  Paolo Strati, MD (1)  ·  Ranjana H Advani, MD (1)  ·  Renata Ferrarotto, M D (1)  ·  Uwe Platzbecker, Prof. Dr. (1)

Results publications

PMID 37651261, PMID 39213421, PMID 39293083, PMID 40364806, PMID 40485906

NIH funding

2016 (1), UM1CA186717 (1)